Amg 410

Phase 1

Amgen

Amg 410 is one of 5 therapeutic programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced or Metastatic Solid TumorsRecruiting

Advanced or Metastatic Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

21 2

Vectibix

Amgen

Phase 1

1 3

Amg 410

Amgen

Phase 1

1 4

ERAS-601

EErasca, Inc.

Preclinical

2 5

ERAS-007

EErasca, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 1Recruiting

Advanced or Metastatic Solid Tumors

NCT07094113

Clinical

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Recruiting· Amgen logo

Amgen·Phase 1·NCT07094113·434 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amg 410. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Amg 410. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Amgen

Amg 410

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Advanced or Metastatic Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News